Trials in follow up

The clinical trials listed in this section are closed to new patient recruitment. For each trial, an overview of the study design is provided together with a brief explanation of the trial objectives. A more detailed overview is available in the AGITG Members Area.

ADJUVANT STUDIES

Upper GI

Oesophageal cancer
DOCTOR –  A Randomised Phase II Trial of Pre-operative cisplatin, 5 fluorouracil and docetaxel ± Radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the oesophagus and/or OG Junction.  Read more

Lower GI

Colorectal Cancer
SCOT –  
A Study of Adjuvant Chemotherapy in Colorectal Cancer.  Read more

A La CaRT  –  Australasian Laparoscopic Cancer of the Rectum Trial:   A phase III prospective randomised trial comparing laparoscopic-assisted resection versus open resection for rectal cancer. Read more

PETACC 6 –  Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer. Read more

 

LOCALLY ADVANCED DISEASE

Upper GI

Biliary Tract Cancer
TACTIC
–  A  phase II trial of panitumumab, cisplatin  and gemcitabine in biliary tract cancer.  Read more

 

PANCREAS CANCER

GAP  –  A Randomised Phase II Study Evaluating Potential Predictive Biomarkers in the Treatment of Locally Advanced and Metastatic Pancreatic Cancer.  Read more

 

COLORECTAL  CANCER

CO.23    –  A phase III randomised study of BBI608 and best supportive care versus placebo and best supportive care in patients with pre-treated advanced colorectal carcinoma.  Read more

ICECREAM  The Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation Among Patients with G13D Mutation.Randomised Phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic CRC with either KRAS WT or G13D mutation.  Read more

 

RARE CANCERS

Gastro-Intestinal Stromal Tumours
Advanced GIST | AG0102 GIST / EORTC 62005
–  Phase III randomised, multi-centre, international trial to determine the relation between dose and clinical activity of STI–571 in patients with unresectable or metastatic malignant gastrointestinal stromal tumors expressing the c–kit receptor tyrosine kinase (CD117). Read more

Adjuvant GIST | EORTC 62024 –  Intermediate and high-risk localised, completely resected, gastro-intestinal stromal tumours (GIST) expressing c-kit receptor: A controlled randomised trial on adjuvant imatinib mesylate (Glivec ®) versus no further therapy after completing surgery. Read more

Donate Now